Last Updated on January 13, 2026 by The Health Master
Solvents
Advisory Issued to All Allopathic Manufacturers
In a major step towards drug safety compliance, Haryana’s Health Minister, Arti Singh Rao, announced that the state has issued an important advisory to all allopathic manufacturers about the increased risk of pharmaceutical solvents procured from either propylene glycol or glycol or glycerin.
The advisory comes in light of past incidents linking certain solvents with heavy risk, calling for pharmaceutical manufacturing standards in place for all regions of the state.
Union Health Minister JP Nadda praised Haryana’s efforts
According to the advisory, manufacturers are advised to be extra cautious about the procurement, stock and use of these three solvents used in medicine deemed ‘risky.’
Arti Singh Rao confirmed that the state government has already embarked upon an inspection and testing drive and is testing and checking such materials in manufacturing lines.
Haryana Health Minister held a virtual meeting with the Union Health Minister
Participants from Haryana:
- Arti Singh Rao, Honb’le Health Minister, Govt. of Haryana.
- Dr. R.S. Dhillon IAS, Secretary, Health Department, Govt. of Haryana.
- Dr. Manoj Kumar IAS, Commissioner FDA Haryana, Govt. of Haryana.
- Lalit Kr. Goel, SDC FDA Haryana, Govt. of Haryana.
- Rakesh Dahiya, ASDC, FDA Haryana, Govt. of Haryana.
Inspections Done; Proactive Actions Confirmed
Ministers have wasted no time acting on their recent announcement.
In an effort to support the state’s commitment to a strong drug regulatory system, statistics from the first part of the drive are impressive:
- State Inspections Conducted: Thus far, there have been 37 state inspections conducted and 54 immediate samples taken.
- Joint inspection: The State and CDSCO have conducted 14 joint inspections and collected 31 samples and sent them for testing and analysis.
Notably, companies that did not meet expectations or need warnings have already received notices.
Additionally, 267 samples associated with these products have been taken from various levels of sales entities within the state and sent for appropriate lab analyses.
Licensed Revocations for Violations
The drive is more than just taking samples; it’s about showing a comprehensive level of oversight through all pharmaceutical manufacturing standards.
According to Arti Singh Rao, Health Minister, there have been risk-based inspections conducted statewide.
Table of RBIs
| Inspection Type | Number Conducted | Severe Action Taken |
| Pharmaceutical Manufacturing Units (RBI) | 33 | 12 firms received orders to stop production, and 2 drug manufacturing licenses were cancelled. |
| Drug Testing Laboratories (RBI) | 17 | The license of one laboratory was cancelled due to significant deficiencies. |
This action including cancelled drug manufacturing licenses sends a strong and severe message to anyone who dares compromise standards and patient safety.
National Acknowledgment & Digital Systems
Health Minister Arti Singh Rao held a virtual meeting through Chandigarh with Union Health Minister JP Nadda, who appreciated Haryana’s efforts towards a strong drug regulatory system, particularly for drug safety compliance.
He also commended them for their efforts on the Online National Drugs Licensing System (ONDLS), an online platform housing all information related to licensing from manufacturing to sales.
All associated licenses are done entirely online, guaranteeing digital transparency.
The Union Minister noted that these efforts are for the sake of a united India, giving effective drug regulatory measures across the nation.
Infrastructure Developments To Come
In the future, laboratory-based oversight is to get a permanent upgrade. Minister Arti Singh Rao notes that construction is currently underway for a new drug laboratory that’s due in four months from today.
To further support infrastructure-based regulatory systems, a proposal will go to CDSCO for additional lab creation in:
- Gurugram
- Hisar
- Karnal
Three laboratories will be constructed through this estimate worth approximately ₹91.9 crore, ensuring world-class pharmaceutical standards will be upheld in the state’s interests over time, guaranteeing the best health for citizens.
Q: What are the ‘risky solvents’ referred to?
The risky solvents referred to are glycol, propylene glycol and glycerin. All of them can be found throughout various medicinal products. However, certain negative incidents worldwide have raised issues about the quality control of solvents—this advisory aims for verification through necessary Propylene Glycol Testing.
Q: What is the Risk Based Inspection (RBI)?
The Risk Based Inspection (RBI) was an additional check where manufactures/labs were prioritized according to historical data of potential risk vs. benefit based on what is produced or manufactured, review history, etc. Thus, contractors needed immediate attention versus those who had spent time in compliance previously.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Key Notes on Revised Schedule M: Compilation
Important short notes for Industry and Regulators
CDSCO Guidelines on Drug Recall
Quality Assurance Vs Quality Control in the Pharma Industry
Major FDA audit findings about Equipment and Instruments
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Drug alert: 112 drug samples declared as NSQ in September 2025
India’s New Live ONDLS Portal Tracks High-Risk Solvents
USFDA inspection with positive VAI to Dr Reddy’s Formulations facility
Drug recall: Glenmark recalls 26,928 packs of oral contraceptives
New Drugs, Medical Devices and Cosmetics Act soon
Govt to amend MDR 2017: New Qualifications for Inspectors and Analysts
Drug recall: Zydus recalls 1512 bottles of Hepatitis B Drug
Govt rolls out incentive scheme for Pharma and MedTech sector
USFDA approval granted for Paroxetine Extended-Release tablets: Alembic
Drug recall: 5 Indian Companies recall drugs over quality issues
